Legend Biotech(us:LEGN)
33.93
-3.22%
Updated on 2025-03-31
Open:33.98
Close:33.93
High:34.41
Low:32.85
Prev Close:35.06
Volume:1.27M
Turnover:42.70M
Turnover Ratio:0.69%
Shares:183.65M
MarketCap:6.23B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 211 | 91698546 | 50.31% | 29 | 81 | 82 |
| 2024-03-31 | 226 | 86578084 | 47.50% | 23 | 86 | 98 |
| 2023-12-31 | 230 | 85900395 | 47.22% | 34 | 93 | 83 |
| 2023-09-30 | 211 | 85955341 | 47.15% | 24 | 70 | 82 |
| 2023-06-30 | 206 | 84530169 | 46.61% | 49 | 59 | 81 |
| 2023-03-31 | 177 | 68006398 | 41.10% | 11 | 80 | 67 |
| 2022-12-31 | 185 | 63932603 | 38.73% | 28 | 58 | 74 |
| 2022-09-30 | 175 | 63801121 | 38.11% | 26 | 80 | 51 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Fmr Llc | 17621599 | 9.67% | 1474567 | 9.13% |
| 2024-06-30 | Price T Rowe Associates Inc /Md/ | 11489275 | 6.30% | 540155 | 4.93% |
| 2024-06-30 | Ra Capital Management, L.P. | 7506934 | 4.12% | 645837 | 9.41% |
| 2024-06-30 | Hhlr Advisors, Ltd. | 6636496 | 3.64% | 651946 | 10.89% |
| 2024-06-30 | Blackrock Inc. | 5721277 | 3.14% | 337247 | 6.26% |
| 2024-06-30 | Westfield Capital Management Co Lp | 4772209 | 2.62% | 2532435 | 113.07% |
| 2024-06-30 | Wellington Management Group Llp | 2809368 | 1.54% | 194945 | 7.46% |
| 2024-06-30 | Janus Henderson Group Plc | 2359056 | 1.29% | 345044 | 17.13% |
| 2024-06-30 | Capital International Investors | 2162711 | 1.19% | -18363 | -0.84% |
| 2024-06-30 | Massachusetts Financial Services Co /Ma/ | 1960709 | 1.08% | 69913 | 3.70% |
About
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
Address:2101 Cottontail Lane
Website:http://www.legendbiotech.com
Market Movers